Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Liver Transplant for Hepatocellular Carcinoma in Post-Milan Criteria Era: A Long-Term Single-Center Experience Publisher Pubmed



Kasraianfard A1, 2 ; Moradi AM1, 2 ; Nassiritoosi M1 ; Jafarian A1, 2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Liver Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Hepatobiliary Surgery and Liver Transplantation Division, Department of General Surgery, Imam Khomeini Hospital Complex, Tehran, Iran

Source: Experimental and Clinical Transplantation Published:2024


Abstract

Objectives: We investigated the outcomes of liver transplant in patients with hepatocellular carcinoma. Materials and Methods: Prospectively, recipients of deceased donor liver transplants from 2007 to 2021 at Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran, were enrolled into the study. The Milan criteria were applied for selection of liver transplant candidates diagnosed with hepatocellular carcinoma. Patients with diagnosis of acute liver failure and who underwent secondary liver transplant were excluded. All patients diagnosed with hepatocellular carcinoma were given mechanistic target of rapamycin inhibitor with calcineurin inhibitor minimization 4 weeks after liver transplant. Patients were assigned to the experimental group (with hepatocellular carcinoma; n = 82) or the control group (without hepatocellular carcinoma; n = 1076). We recorded the etiologies of liver cirrhosis in the experimental group, demographic data from all patients, and postoperative complications. Results: Of 1158 total patients, mean age was 44.15 ± 14.71 years (range, 1-73 years) and 712 were male patients (61.5%). In the experimental group (n = 82), there were 76 patients (92.68%) who were within the Milan criteria; others were excluded intraoperatively. All patients were followed for a median of 65.3 ± 40.8 months (range 10-197 months). Patient survival rates in the experimental group and control group at 3 months, 1 year, and 3 years were 89%, 80%, and 78% versus 84%, 81%, and 70%, respectively (P = .742). Hepatocellular carcinoma reoccurred in 6 patients (7.31%) at mean of 16.83 months postoperatively. Conclusions: Liver transplant for patients with hepatocellular carcinoma in the post-Milan criteria era is associated with acceptable outcomes. © Baskent University 2024 Printed in Turkey. All Rights Reserved.